Showing results (81-90 of 128) with videos related to
Sort By:
Pageof 13
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 21, 2013
TH2 cytokines from malignant cells suppress TH1 responses and enforce a global TH2 bias in leukemic cutaneous T-cell lymphomaEmmanuella Guenova, Rei Watanabe, Jessica E Teague, et al.Journal of the American Academy of Dermatology|February 19, 2013
Improvement in peripheral blood disease burden in patients with Sézary syndrome and leukemic mycosis fungoides after total skin electron beam therapyRachel S Klein, James D Dunlop, Sara S Samimi, et al.Blood|January 13, 2006
Quantitative PCR on 5 genes reliably identifies CTCL patients with 5% to 99% circulating tumor cells with 90% accuracyMichael Nebozhyn, Andrey Loboda, Laszlo Kari, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 11, 2010
Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphomaSean J Whittaker, Marie-France Demierre, Ellen J Kim, et al.Schizophrenia Research|September 8, 2012
Pimavanserin, a selective serotonin (5-HT)2A-inverse agonist, enhances the efficacy and safety of risperidone, 2mg/day, but does not enhance efficacy of haloperidol, 2mg/day: comparison with reference dose risperidone, 6mg/dayHerbert Y Meltzer, Helio Elkis, Kimberly Vanover, et al.JAMA Dermatology|December 30, 2020
Brentuximab Vedotin for Relapsed or Refractory Sézary SyndromeDaniel J Lewis, Paul L Haun, Sara S Samimi, et al.Blood Advances|April 14, 2023
Identifying highly active anti-CCR4 CAR T cells for the treatment of T-cell lymphomaKeisuke Watanabe, Angela M Gomez, Shunichiro Kuramitsu, et al.Urology|June 21, 2021
A Novel Risk Prediction Model to Triage Difficult Urethral CatheterizationsAlbert S Ha, Jamie Pak, Christopher R Haas, et al.Archives of Dermatology|August 17, 2011
High clinical response rate of Sezary syndrome to immunomodulatory therapies: prognostic markers of responseBrian A Raphael, Daniel B Shin, Karen R Suchin, et al.Blood|August 1, 2015
Topical resiquimod can induce disease regression and enhance T-cell effector functions in cutaneous T-cell lymphomaAlain H Rook, Joel M Gelfand, Joel C Gelfand, et al.Pageof 13